Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (100.2)	$ 243.1	$ 340.5
Noncash items:
Depreciation	36.0	31.8	40.8
Amortization	99.6	106.0	82.8
Allowance for credit losses	7.1	4.8	5.6
Stock-based compensation expense	30.7	30.5	28.2
Gain on equity investments, net	(3.6)	0.0	0.0
Gain on sale of property, plant and equipment	(5.4)	(1.9)	(2.2)
Gain on sale of KaVo treatment unit and instrument business	0.0	(8.9)	(11.7)
Restructuring charges	1.3	4.7	10.8
Goodwill and intangible asset impairment	258.3	0.0	0.0
Other impairment charges	0.2	6.4	18.4
Fair value adjustment of acquisition-related inventory	0.0	9.5	0.0
Amortization of right-of-use assets	27.0	24.3	28.3
Inducement expense related to exchange of convertible notes	28.5	0.0	0.0
Amortization of debt discount and issuance costs	4.6	4.1	23.3
Change in deferred income taxes	(37.0)	(29.0)	(59.0)
Change in trade accounts receivable	(17.0)	(71.0)	(43.2)
Change in inventories	35.1	(39.9)	(66.0)
Change in trade accounts payable	(46.3)	44.5	(20.3)
Change in prepaid expenses and other assets	3.3	(11.7)	(11.5)
Change in accrued expenses and other liabilities	(12.0)	(133.0)	34.3
Change in operating lease liabilities	(34.5)	(31.6)	(37.5)
Net cash provided by operating activities	275.7	182.7	361.6
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(58.2)	(75.7)	(54.7)
Proceeds from sales of property, plant and equipment	6.1	3.3	11.6
Proceeds from sale of equity investment	10.7	0.0	0.0
Acquisitions, net of cash acquired	0.0	(696.2)	(2.1)
Proceeds from sale of KaVo treatment unit and instrument business, net	0.0	73.9	312.5
Proceeds from the settlement of derivative financial instruments	1.6	56.0	11.4
All other investing activities, net	(22.6)	(18.6)	(16.0)
Net cash (used in) provided by investing activities	(62.4)	(657.3)	262.7
Cash flows from financing activities:
Proceeds from issuance of convertible notes due 2028	500.2	0.0	0.0
Principal paid related to exchange of convertible notes due 2025	(401.2)	0.0	0.0
Proceeds from borrowings	323.5	0.3	0.0
Repayment of borrowings	(288.8)	(0.5)	(475.7)
Proceeds from revolving line of credit	0.0	124.0	0.0
Repayment of revolving line of credit	0.0	(124.0)	0.0
Proceeds from stock option exercises	11.3	21.8	19.5
Tax withholding payment related to net settlement of equity awards	(7.9)	(9.1)	(7.2)
All other financing activities	0.1	0.0	0.1
Net cash provided by (used in) financing activities	118.9	12.5	(465.6)
Effect of exchange rate changes on cash and cash equivalents	0.9	(4.6)	26.0
Net change in cash and cash equivalents	333.1	(466.7)	184.7
Beginning balance of cash and cash equivalents	606.9	1,073.6	888.9
Ending balance of cash and cash equivalents	940.0	606.9	1,073.6
Supplemental data:
Cash paid for interest	63.2	38.4	35.7
Cash paid for taxes	98.6	119.2	84.0
ROU assets obtained in exchange for operating lease obligations	22.1	36.0	24.7
Convertible senior notes due 2028 (the “2028 Convertible Notes”)
Cash flows from financing activities:
Debt issuance costs related to issuance of convertible notes due 2028	(13.8)	0.0	0.0
Debt issuance costs related to other borrowings	(13.8)	0.0	0.0
Other Borrowings
Cash flows from financing activities:
Debt issuance costs related to issuance of convertible notes due 2028	(4.5)	0.0	(2.3)
Debt issuance costs related to other borrowings	$ (4.5)	$ 0.0	$ (2.3)